MapLight Therapeutics
MPLT
100 hedge funds and large institutions have $868M invested in MapLight Therapeutics in 2026 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 19 increasing their positions, 28 reducing their positions, and 8 closing their positions.
350% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 8
73% more capital invested
Capital invested by funds: $502M → $868M (+$366M)
23% more funds holding
Funds holding: 81 → 100 (+19)
1.36% less ownership
Funds ownership: 58.21% → 56.84% (-1.4%)
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
32% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 28
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $907K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$37.7M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$19.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$14.8M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$12M |
| 5 |
BCM
Boxer Capital Management
San Diego,
California
|
+$2.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$10M |
| 2 |
BlackRock
New York
|
-$9.05M |
| 3 |
BOCH
Blue Owl Capital Holdings
New York
|
-$7.94M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$5.05M |
| 5 |
FGP
Freestone Grove Partners
San Francisco,
California
|
-$4.17M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RCM
101
RA Capital Management
Boston,
Massachusetts
| – | -$5.05M | -248,294 | Closed |
|
|
BOTOTLSJU
102
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
| – | -$4.05M | -199,231 | Closed |
|
|
TAM
103
TFG Asset Management
Grand Cayman,
Cayman Islands
| – | -$2.28M | -112,115 | Closed |
|
104
Walleye Capital
New York
| – | -$235K | -11,572 | Closed |
|
|
SO
105
STRS Ohio
Columbus,
Ohio
| – | -$61K | -3,000 | Closed |
|
|
RFP
106
Root Financial Partners
Encinitas,
California
| – | -$569 | -28 | Closed |
|
|
MCM
107
MAI Capital Management
Independence,
Ohio
| – | -$244 | -12 | Closed |
|
|
TWD
108
True Wealth Design
Akron,
Ohio
| – | -$61 | -3 | Closed |
|
MPLT Hedge Fund Activity: Q2 2026 in Review
100 of the 8,153 institutional investors tracked by Wall St. Rank reported a position in MapLight Therapeutics (MPLT) for Q2 2026, worth a combined $868M — up 73% from $502M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new MPLT positions and 8 closed out — a net gain of 28 holders — while 19 added to existing stakes and 28 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $37.7M. The largest seller was ADAR1 Capital Management, cutting an estimated $10M.
- 100 institutional investors held MapLight Therapeutics (MPLT) as of Q2 2026, up from 81 in Q1 2026.
- Funds reported $868M of MapLight Therapeutics stock for Q2 2026, up 73% quarter-over-quarter.
- 36 funds opened new MapLight Therapeutics positions in Q2 2026 and 8 closed out, a net change of +28 holders.
- The largest MapLight Therapeutics buyer in Q2 2026 was T. Rowe Price Associates, an estimated $37.7M added.
- The largest MapLight Therapeutics seller in Q2 2026 was ADAR1 Capital Management, an estimated $10M sold.
Based on aggregated 13F filings for Q2 2026.